Since Cheung et al. [59] have demonstrated the involvement of TRPC4 and TRPC5 channels in adverse reactions to the potent cancer cell-specific cytotoxic agent (-)-Englerin A, situations may be envisaged wherein TRPC4 channel inhibition by SWCNTs carrying anti-cancer drugs may even be beneficial. Here, TRPC4 is linked to cancer.